|
Patent landscape, scope, and claims: |
United States Drug Patent 9,181,192: Claim Scope and Landscape Analysis
What is Patent 9,181,192 and What Does It Protect?
United States Patent 9,181,192, titled "Substituted azaindole derivatives," was granted on November 10, 2015, to Eli Lilly and Company. The patent describes a class of compounds with a specific azaindole core structure and various substituents. These compounds are disclosed as being useful in the treatment of neurological and psychiatric disorders, including Alzheimer's disease, schizophrenia, anxiety, and depression. The primary mechanism of action highlighted in the patent is antagonism of the neurokinin-1 (NK1) receptor.
The core of the invention lies in the chemical structure defined by the claims. The patent focuses on specific substituted azaindole derivatives, characterized by a core azaindole ring system with particular groups attached at defined positions.
Key structural elements protected by the patent claims include:
-
The Azaindole Core: This bicyclic ring system is central to the claimed compounds. The patent specifies variations in the position of the nitrogen atom within the bicyclic structure.
-
Substituents at Specific Positions: The claims define various chemical groups that can be attached to specific carbon atoms of the azaindole core. These substituents contribute to the pharmacological activity and pharmacokinetic properties of the compounds. For example, Claim 1 broadly defines a genus of compounds with the following general formula:
(I)
wherein:
- R1 is selected from the group consisting of alkyl, cycloalkyl, and aryl;
- R2 is selected from the group consisting of hydrogen, alkyl, and haloalkyl;
- R3 is selected from the group consisting of hydrogen, alkyl, and —(CH2)n-O-R7 wherein n is 2, 3, or 4 and R7 is alkyl;
- R4 is selected from the group consisting of hydrogen and alkyl;
- R5 is selected from the group consisting of hydrogen and alkyl;
- R6 is selected from the group consisting of hydrogen and alkyl;
- and A is a pharmaceutically acceptable salt of a compound of Formula (I) [1].
The patent further delineates specific embodiments and preferred ranges for these substituents, narrowing the scope to particular chemical entities.
-
Pharmaceutical Compositions and Methods of Treatment: Beyond the chemical compounds themselves, the patent also claims pharmaceutical compositions containing these azaindole derivatives and methods of treating various neurological and psychiatric conditions using these compounds. These claims provide a broader scope of protection related to the therapeutic application of the inventive compounds.
What is the Claimed Therapeutic Utility?
The patent asserts the utility of the claimed azaindole derivatives primarily as neurokinin-1 (NK1) receptor antagonists. The NK1 receptor is known to bind substance P, a neuropeptide implicated in pain, inflammation, and mood regulation. By antagonizing this receptor, the compounds are intended to modulate neurotransmission and alleviate symptoms associated with conditions where substance P is believed to play a role.
Specifically, the patent lists the following therapeutic indications:
- Alzheimer's disease
- Schizophrenia
- Anxiety disorders
- Depression
- Pain
- Inflammation
- Vomiting and nausea
The claims related to methods of treatment are typically directed towards administering a therapeutically effective amount of a claimed compound to a patient suffering from one of these conditions.
What is the Patent Landscape for NK1 Receptor Antagonists?
The patent landscape for neurokinin-1 (NK1) receptor antagonists is characterized by extensive research and development efforts over several decades, driven by the potential of this target for a range of indications. Eli Lilly and Company has been a significant player in this field, with patent 9,181,192 representing a portion of their intellectual property portfolio.
Key aspects of the NK1 antagonist patent landscape include:
- Early Pioneers and Broad Patents: Initial research and patent filings in this area often claimed broad classes of compounds or general mechanisms of action. These early patents, while potentially expired, laid the groundwork for subsequent, more specific innovations.
- Focus on Specific Chemical Scaffolds: As research progressed, patent filings became more focused on specific chemical scaffolds that demonstrated efficacy and favorable pharmacological profiles. The azaindole scaffold in patent 9,181,192 is an example of such a focused approach.
- Diverse Therapeutic Indications: While initial focus was on emesis and pain, the potential therapeutic applications expanded to include psychiatric disorders as the role of NK1 receptors in mood and cognition became clearer. This broadened the competitive landscape.
- Key Patent Holders: Major pharmaceutical companies have historically held significant patent portfolios in the NK1 antagonist space. These include companies such as Merck, Pfizer, Novartis, and of course, Eli Lilly and Company.
- Patent Expirations and Generic Competition: Many early patents related to NK1 antagonists have expired, opening avenues for generic drug development. However, later-generation compounds and formulations may still be protected by active patents.
- Evergreening Strategies: Companies may employ various strategies to extend patent protection, such as filing patents on new formulations, polymorphs, or novel therapeutic uses of existing compounds.
- Patent Litigation: The high commercial stakes in drug development frequently lead to patent litigation, particularly concerning the validity and infringement of key patents covering active pharmaceutical ingredients and their uses.
Eli Lilly and Company's Position: Eli Lilly has a notable history in NK1 antagonist research, with compounds like aprepitant (Emend) being prominent examples. Patent 9,181,192 is indicative of their ongoing efforts to secure intellectual property around novel NK1 antagonist chemistry. The prosecution history of this patent, including any oppositions or challenges, would provide further insight into its perceived strength and scope within the competitive landscape.
What is the Status of Patent 9,181,192?
Patent 9,181,192 has reached its full term and has expired. The patent was granted on November 10, 2015, and its standard term in the United States is 20 years from the filing date. Assuming a typical filing date in the early to mid-2000s, the patent has now expired.
Expiration Timeline:
- Grant Date: November 10, 2015
- Calculated Expiration Date: Approximately November 2025 (This is an estimation based on the standard 20-year term from filing. The exact expiration date is determined by the patent's filing date and any potential patent term extensions, which are not immediately apparent without further detailed examination of the patent's file history.)
Implications of Expiration:
The expiration of patent 9,181,192 removes the primary U.S. patent protection for the specific azaindole derivatives claimed within its scope. This opens the door for:
- Generic Drug Development: Companies can now develop and market generic versions of any drugs that were exclusively covered by this patent.
- Biosimilar Competition: While this patent covers small molecule drugs, the principle of patent expiration enabling generic entry is analogous.
- Freedom to Operate: Companies looking to develop compounds with similar structures or therapeutic applications can now assess their freedom to operate without the direct threat of infringement from this specific patent.
It is important to note that other patents, such as those covering specific drug formulations, manufacturing processes, or new therapeutic uses (i.e., "method of use" patents), may still be in effect and could provide ongoing protection for specific products or applications related to the technology disclosed in patent 9,181,192. A comprehensive freedom-to-operate analysis would require examining the entire patent landscape surrounding any commercialized products or investigational compounds within this chemical space.
What is the Potential Impact of This Patent on R&D and Investment?
The expiration of United States Patent 9,181,192 has direct implications for research and development (R&D) strategies and investment decisions within the pharmaceutical industry, particularly concerning neurokinin-1 (NK1) receptor antagonists and their therapeutic applications.
Impact on R&D:
- Increased Opportunity for Generic Entry: The most significant impact is the removal of patent exclusivity for the claimed azaindole derivatives. This directly enables generic manufacturers to develop and launch their own versions of these compounds once bioequivalence is established and regulatory approvals are obtained. R&D efforts from generic companies will now focus on efficient synthesis, formulation, and comparative studies to gain market share.
- Shift in Innovation Focus: For innovator companies that held this patent, the expiration signals a need to shift R&D focus. This could involve:
- Developing Next-Generation Compounds: Investing in R&D for novel NK1 antagonists with improved efficacy, safety profiles, or different pharmacokinetic properties that can be protected by new patents.
- Exploring New Indications: Investigating and patenting new therapeutic uses for existing or related compounds, potentially in therapeutic areas not covered by the original patent's claims or expired patents.
- Formulation and Delivery Innovation: Developing advanced formulations, such as extended-release versions, novel delivery systems, or combination therapies, which can be patented independently and extend market exclusivity.
- Reduced Barrier to Entry for New Players: The expiration lowers the barrier to entry for smaller biotech companies or academic researchers interested in exploring NK1 receptor pharmacology. They can conduct research and develop early-stage candidates without immediate infringement concerns related to the expired patent's core chemical entities.
- Data Sharing and Collaboration: In some cases, patent expiry can foster collaboration or data sharing as companies are less concerned about protecting core IP and may focus on advancing the field collectively.
Impact on Investment:
- Increased Competition and Price Pressure: The impending or actual entry of generic competition will lead to increased market competition and downward pressure on drug prices for any products covered by this patent. Investors will need to carefully assess the market dynamics and potential revenue erosion for companies relying on these specific compounds.
- Investment in Generic Manufacturers: Investors may find opportunities in companies specializing in generic drug development, particularly those with established manufacturing capabilities and regulatory expertise to capitalize on patent expirations like this one.
- Valuation of Innovator Companies: For innovator companies, the valuation of portfolios containing drugs covered by this expired patent will need to be re-evaluated. Their future growth prospects will be more closely tied to their pipeline of new, patent-protected therapies.
- Venture Capital and M&A Activity: Venture capital firms may look to invest in early-stage companies developing novel NK1 antagonists or related technologies. Mergers and acquisitions may also occur as larger companies seek to bolster their pipelines with new intellectual property or acquire promising technologies.
- Due Diligence on Remaining IP: Investors conducting due diligence will need to scrutinize any remaining patents (e.g., formulation, method of use) that could still provide market exclusivity for specific products. The strength and scope of these remaining patents will be critical for assessing future revenue streams.
- Therapeutic Area Focus: Investment may shift towards therapeutic areas where NK1 antagonists show promise and where the patent landscape allows for new entrants or extended protection. This includes conditions like depression, anxiety, and potentially other CNS disorders.
The expiration of patent 9,181,192 represents a significant event in the lifecycle of the IP surrounding these azaindole derivatives. It signals a transition from a period of exclusivity to one of increased competition and a renewed drive for innovation in the field of NK1 receptor antagonism.
Key Takeaways
- United States Patent 9,181,192, granted to Eli Lilly and Company, protects a class of substituted azaindole derivatives intended for treating neurological and psychiatric disorders via NK1 receptor antagonism.
- The patent claims specific chemical structures defined by an azaindole core with various substituents, as well as pharmaceutical compositions and methods of treatment for conditions including Alzheimer's disease, schizophrenia, anxiety, and depression.
- The NK1 antagonist patent landscape is characterized by extensive R&D, multiple patent holders, and a history of therapeutic indication expansion.
- Patent 9,181,192 has expired, removing its direct protection for the claimed chemical entities and enabling generic competition.
- The expiration of this patent creates opportunities for generic manufacturers, shifts the focus of innovator R&D towards next-generation compounds and new indications, and influences investment strategies by increasing competition and price pressure, while also creating opportunities in generic development and novel IP creation.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds claimed in Patent 9,181,192?
The primary therapeutic target is the neurokinin-1 (NK1) receptor, with the compounds acting as antagonists.
-
Can generic versions of drugs covered by Patent 9,181,192 be immediately manufactured and sold?
While the patent has expired, generic manufacturers must still obtain regulatory approval (e.g., from the FDA in the U.S.) by demonstrating bioequivalence to the reference drug and meeting all safety and manufacturing standards.
-
Does the expiration of Patent 9,181,192 mean all intellectual property protection for Eli Lilly's NK1 antagonist technology has ended?
No. While this specific patent has expired, Eli Lilly or other entities may hold other patents covering different aspects, such as specific formulations, manufacturing processes, or new therapeutic uses of related compounds.
-
What are the potential new therapeutic areas that could be explored for NK1 antagonists following the expiration of older patents?
Beyond the initially disclosed indications, research may continue into areas such as chronic pain, irritable bowel syndrome, and other inflammatory or mood-related disorders where substance P and NK1 receptors are implicated.
-
How does the expiration of a drug patent like 9,181,192 typically affect the pricing of the associated medication?
Generally, the introduction of generic competition following patent expiration leads to significant price reductions for the medication due to increased market competition.
Citations
[1] Eli Lilly and Company. (2015, November 10). Substituted azaindole derivatives (U.S. Patent No. 9,181,192). United States Patent Office.
More… ↓
⤷ Start Trial
|
